XTX Topco Ltd Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

XTX Topco Ltd decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 69.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,057 shares of the biopharmaceutical company’s stock after selling 2,364 shares during the period. XTX Topco Ltd’s holdings in Regeneron Pharmaceuticals were worth $1,111,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in REGN. Mark Sheptoff Financial Planning LLC raised its stake in shares of Regeneron Pharmaceuticals by 35.0% during the second quarter. Mark Sheptoff Financial Planning LLC now owns 135 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 35 shares in the last quarter. MRP Capital Investments LLC bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $306,000. Vanguard Personalized Indexing Management LLC raised its position in Regeneron Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 9,559 shares of the biopharmaceutical company’s stock valued at $10,047,000 after purchasing an additional 1,129 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 5.4% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,314 shares of the biopharmaceutical company’s stock worth $2,432,000 after buying an additional 119 shares during the period. Finally, Argent Trust Co grew its position in shares of Regeneron Pharmaceuticals by 1.3% during the 2nd quarter. Argent Trust Co now owns 2,370 shares of the biopharmaceutical company’s stock worth $2,491,000 after buying an additional 31 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 0.4 %

NASDAQ:REGN opened at $1,145.03 on Friday. The company has a market capitalization of $126.17 billion, a P/E ratio of 33.83, a PEG ratio of 3.93 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The firm has a fifty day simple moving average of $1,131.75 and a 200-day simple moving average of $1,032.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $8.79 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on REGN. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Piper Sandler lifted their price objective on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Finally, TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,111.30.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Bonnie L. Bassler sold 756 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold a total of 10,026 shares of company stock worth $11,498,705 over the last quarter. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.